Credit Suisse Starts AC Immune SA (ACIU) at Outperform

October 18, 2016 6:29 AM EDT
Get Alerts ACIU Hot Sheet
Price: $14.56 -2.35%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 50 | New: 20
Trade ACIU Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Credit Suisse initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $18.00.

Analyst Alethia Young commented, "AC Immune is focused on neurodegenerative diseases, primarily Alzheimer’s Disease (AD). Their lead asset, crenezumab, is in Phase 3 in partnership with Roche. AC Immune is developing more than just crenezumab which allows for some optionality with early AD targets like Tau or AD vaccines. In this report, we will focus on near-term catalyst which will be a stock read-through from a competitive Phase 3 program being developed by Lilly. We view this story as high risk/high reward in the nearterm. In the long-term post the headline risk, we are positive for 3 reasons: 1) no AD asset is exactly the same and designs differ so it will be uncertain that if solanezumab (Sola) fails all drugs fail, 2) their Ph3 and Biogen's (another competitor) will continue even if Lilly is a complete fail, and 3) AC Immune has other assets that could be used in combination or separately from crenezumab."

For an analyst ratings summary and ratings history on AC Immune SA click here. For more ratings news on AC Immune SA click here.

Shares of AC Immune SA closed at $14.43 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Credit Suisse

Add Your Comment